Seres Therapeutics, Inc. (MCRB)
| Previous close | 5.44 |
| Open | 5.39 |
| Bid | 5.40 x 1200 |
| Ask | 5.41 x 800 |
| Day's range | 5.32 - 5.52 |
| 52-week range | 2.50 - 9.49 |
| Volume | |
| Avg. volume | 728,047 |
| Market cap | 671.551M |
| Beta (5Y monthly) | 2.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.43 |
- Business Wire
Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
CAMBRIDGE, Mass., February 08, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that enrollment in Cohort 2 in its SER-155 Phase 1b study is underway. SER-155, an investigational oral microbiome therapeutic, is designed to reduce the incidence of gastrointestinal (GI) infections, bloodstream infections, and graft versus host disease (GvHD) in individuals undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., February 03, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on February 1, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 48,750 shares of its common stock to eleven new employees, consisting of stock options to purchase an aggregate of 32,500 shares of common stock and restricted stock units ("RSUs"), cov
- Simply Wall St.
Seres Therapeutics' (NASDAQ:MCRB) investors will be pleased with their respectable 70% return over the last three years
The last three months have been tough on Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders, who have seen the share...
